SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms Inc. is experiencing a sharp sell-off as investors react to unfavorable court rulings regarding addictive content and rising concerns over heavy AI capital expenditure. The community is actively debating whether this decline represents a major buying opportunity due to strong fundamentals or a deeper structural shift in social media regulation.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as investors react to volatility driven by reports of Google's new memory compression technology, which some fear could reduce future demand for traditional memory chips. The community remains deeply divided, with many bulls highlighting the company's strong fundamentals and critical role in the AI supply chain, while others are caught in a broader market sell-off triggered by geopolitical tensions and concerns over cyclicality.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is experiencing extreme volatility as traders grapple with escalating geopolitical tensions and erratic energy markets, fueling intense community debate over whether to buy the dip or prepare for further downside. Investors are closely monitoring potential diplomatic developments regarding the Strait of Hormuz, with the discourse split between those aggressively scalping the swings and others cautioning that leveraged semi-conductor exposure remains a risky play amidst broader economic uncertainty.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is seeing renewed positive momentum driven by a strategic ad partnership with Pacvue that expands its enterprise-scale advertising capabilities. Investors are closely watching ongoing insider buying, which appears to be tempering concerns surrounding previous executive stock sales.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is gaining momentum as investors eye its dual GLP-1/GIP agonist, VK2735, as a high-potential challenger in the multibillion-dollar obesity market. The community remains focused on upcoming trial milestones, viewing the stock as a prime acquisition target due to its clinical progress and clean profile relative to competitors.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals is seeing heightened investor attention and a strong upward trend, driven by robust commercial execution of its lead therapy, Rezdiffra, and speculation regarding potential long-term acquisition interest from major biopharma players. While the community is actively debating the company's high operating expenses versus its market leadership in the MASH space, technical momentum and positive analyst coverage continue to fuel significant bullish sentiment.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Kodiak Sciences is surging after the GLOW2 Phase 3 study for its eye drug, Zenkuda, met primary endpoints with superior results compared to sham treatment. The community is actively discussing a potential short squeeze due to high short interest, while debating whether the current move marks a long-term rerating of the company's platform or a temporary spike prone to profit-taking.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

Wave Life Sciences is experiencing heightened market attention following a volatile reaction to interim clinical data for its obesity candidate, WVE-007, which has sparked intense debate over its long-term potential compared to GLP-1 incumbents. While some investors are bullish on the company's RNA-based platform and its unique ability to reduce visceral fat while preserving muscle mass, others remain skeptical about the trial design and are wary of potential further downside as analysts balance ambitious price targets against the challenges of a crowded obesity pipeline.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV investors are reacting negatively to a recent reverse stock split, with many in the community expressing extreme frustration over a lack of communication from management and a sharp decline in share price. Discussion is dominated by concerns over the company's long-term viability, allegations of market manipulation, and intense debate regarding whether the stock is an oversold buying opportunity or a value trap heading toward bankruptcy.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing significant selling pressure as investors grapple with concerns over high AI capital expenditures and a potential slowdown in software revenue growth, leading to a persistent decline in share price. The community is deeply divided between those viewing the current drop as an oversold, generational buying opportunity and those fearing a deeper structural breakdown in the stock's long-term momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data

Can-Fite stock jumps 20% after mid-stage data show namodenoson is well tolerated in advanced pancreatic cancer patients, meeting the study's primary safety endpoint.

Power, Compute and Breakthrough Science

Today’s headlines underscore a decisive shift toward owning the infrastructure, power, and materials that will underpin the next phase of the AI economy, including $KBLB, $VCIG, $CANF, $ASNS, $BW, and $APLD

<ul class="summary-bullets"><li>The study enrolled 20 high-risk patients with advanced, metastatic disease who had received one or more prior therapies.</li><li>The company said that the secondary endpoints included overall and progression-free survival.</li><li>Can-Fite announced exercise of certain outstanding warrants to purchase up to 795,869 ADS at a reduced price of $5 per share.&nbsp;</li></ul>Shares of Can-Fite BioPharma (CANF) surged more than 40% in pre-market trading on Wednesday after the company reported positive results from its Phase 2A open-label study of namodenoson in patients with advanced pancreatic ductal adenocarcinoma (PDAC) who had previously failed other treatments.The trial met its primary safety endpoint, showing that the drug was very well tolerated, with no new safety concerns observed. The study enrolled 20 high-risk patients with advanced, metastatic disease who had received one or more prior therapies.The company said that the secondary endpoints included overall and progression-free survival, with follow-up ongoing and one-third of patients still alive at data cut-off, as more mature results are expected to be presented at upcoming scientific meetings.Namodenoson is a selective A3 adenosine receptor agonist that has shown anti-tumor activity in preclinical models and is also being studied in advanced liver cancer. The drug has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer.<h2 class="st-heading-2">Exercising of Warrants for $4.0 Million Proceeds</h2>Can-Fite BioPharma also announced a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to 795,869 American Depositary Shares at a reduced price of $5 per share, down from $9.34. The transaction is expected to close around March 5, 2026.&nbsp;In connection with the cash exercise, the company will issue new unregistered warrants to purchase up to 1,591,738 ADSs at $5 per share, exercisable for 24 months.&nbsp;Can-Fite expects gross proceeds of about $4.0 million to support research, clinical trials, and general corporate purposes.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/CANF">CANF</a> on Stocktwits turned 'extremely bullish' from 'bullish' a day earlier, amid 'extremely high' message volumes.<img src="https://news.stocktwits-cdn.com/CANF_jpg_27fa5e9013.webp" alt="CANF.jpg">One user said the company is a "great buyout candidate."<stembedurl>https://stocktwits.com/Pindis7/message/646561779</stembedurl>Year-to-date, the stock gained 63%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did CANF Stock Soar 25% Today?

CANF company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.

Equity

The company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.

This Microcap Just Locked Up New IP in a Massive Pharma Market

In biotechnology, intellectual property wins often act as quiet but powerful catalysts, particularly when they extend a platform into new therapeutic categories or unlock access to large international markets. As competition intensifies and pipelines mature, patent protection remains a key driver of long-term value, especially for companies advancing novel mechanisms with broad clinical applicability.Shares of Can-Fite BioPharma Ltd. (NYSE American: CANF) are surging Friday after the company announced it was granted a new patent in Brazil covering the treatment of sexual dysfunction. The ...

<ul class="summary-bullets"><li>Can-Fite is advancing its proprietary A3AR agonist platform across multiple indications, including oncology and inflammatory diseases.</li><li>The new patent expands Can-Fite’s IP coverage in Brazil and opens up potential commercialization opportunities in the Latin American market.</li><li>On Tuesday, the company approved a 1-for-3,000 reverse split effective Jan. 5, 2026, on the Tel Aviv Stock Exchange, alongside an ADS ratio change on the NYSE at a 1-for-20 reverse split.</li></ul>NYSE-listed shares of Can-Fite BioPharma (CANF) surged 50% in premarket trading on Friday, after the company secured a Brazilian patent for its treatment of sexual dysfunction, opening the door to potential commercialization opportunities in Latin America.<a href="https://stocktwits.com/symbol/CANF">Can-Fite BioPharma</a> announced that Brazil’s Patent Office has granted a patent covering the use of its A3 adenosine receptor (A3AR) agonists for the treatment of sexual dysfunction. The new patent expands Can-Fite’s IP coverage in Brazil, a key Latin American pharmaceutical market with increasing demand for treatments targeting sexual health.<h2 class="st-heading-2">Can-Fite’s A3AR Agonist Platform</h2>Sexual dysfunction is linked to vascular, inflammatory, and metabolic pathways, and Can-Fite’s preclinical and clinical research suggests that A3AR activation may help regulate key signaling mechanisms involved in erectile and sexual function. Can-Fite is advancing its proprietary A3AR agonist platform across multiple indications, including oncology and inflammatory diseases, while exploring additional non-oncologic applications.“The grant of this Brazilian patent further validates the therapeutic versatility of A3 adenosine receptor agonists and expands our intellectual-property footprint in a major pharmaceutical market. This patent complements our broader clinical and preclinical programs and may create future partnering or commercialization opportunities in Latin America,” said Pnina Fishman, Chairperson and Chief Scientific Officer at Can-Fite BioPharma.<h2 class="st-heading-2">Reverse Stock Spilt</h2>On Tuesday, Can-Fite BioPharma approved a 1-for-3,000 reverse split of its ordinary shares, which will&nbsp;be recorded on the Tel Aviv Stock Exchange on January 2, 2026, with trading in the newly consolidated shares set to begin on January 5, 2026.At the same time, Can-Fite will adjust the ratio of its American Depositary Shares (ADS) traded on the NYSE. The ADS ratio will change from one ADS representing 300 ordinary shares to one ADS representing two ordinary shares, an adjustment equivalent to a 1-for-20 ADS split.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes.One user was speculating on the stock price post reverse split.<stembedurl>https://stocktwits.com/Dansaidso/message/640149218</stembedurl>Year-to-date, the stock has been under heavy selling pressure, losing more than 85%.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/mag-7-2025-review-on-charts/cLeU7wOREwN">As 2025 Bids Adieu, A Look At How Mag 7 Stocks Are Positioned On Charts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stocks, shares background - stock photo (representative image courtesy of Sean Gladwell via Getty Images)

Can-Fite BioPharma Shares Surged 50% In Pre-Market On Brazilian Patent Win

The company said it was granted a patent covering the use of its A3 adenosine receptor agonists for the treatment of sexual dysfunction in Brazil.

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.

Can-Fite Biopharma Ltd - ADR

Alphabet $GOOGL

Robinhood $HOOD

Rocket Lab $RKLB

Sandisk $SNDK

The ticker that owned the conversation. This award honors the stock that defined the market narrative through engagement, price action, and cultural presence on the boards.

CANF
Can-Fite BioPharma Ltd.

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest CANF News

CANFCan-Fite BioPharma Ltd.